Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

22.34 -0.45 (-1.95%)

Streaming Delayed Price Updated: 1:31 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today ↗

December 30, 2025

One analyst sees significant upside for the stock after yesterday's sell-off.

Via The Motley Fool

Ultragenyx Stock Eyes Best Day In 17 Months As Wall Street Shifts Focus To 2026 Pipeline After Bone Disease Trial Miss ↗

December 30, 2025

The rally reflects renewed investor attention on longer-term pipeline catalysts and regulatory milestones rather than the recent late-stage trial setback.

Via Stocktwits

Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today ↗

December 29, 2025

A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3.

Via The Motley Fool

Which stocks are experiencing notable movement on Monday? ↗

December 29, 2025

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

What to Expect from Ultragenyx Pharmaceutical's Earnings ↗

August 04, 2025

Via Benzinga

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

Keep an eye on the top gainers and losers in Monday's session. ↗

December 29, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Why Did RARE Stock Plunge Over 41% Today? ↗

December 29, 2025

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program.

Via Stocktwits

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status ↗

September 09, 2025

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

Via Benzinga

Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts ↗

September 05, 2025

Via Benzinga

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To Know ↗

August 06, 2025

Via Benzinga

Ultragenyx (RARE) Q2 Revenue Up 13% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss ↗

August 05, 2025

Ultragenyx Q2 2025 earnings show revenue beat and narrower loss, reaffirming full-year guidance. Shares rose slightly post-report amid mixed market sentiment.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 04, 2025

Via Benzinga

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks ↗

July 28, 2025

HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical Stock ↗

July 28, 2025

Via Benzinga

FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst ↗

July 14, 2025

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.

Via Benzinga

Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection ↗

July 14, 2025

The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.

Via Investor's Business Daily

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN) ↗

July 11, 2025

Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show.

Via Chartmill

Topics World Trade

Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views ↗

July 10, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

July 10, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 10, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.